ClinicalTrials.gov
public full text
Public Domain
WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors
In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant brain tumor that is refractory to standard treatment and is without known cure.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Prolonged survival in pediatric diffuse intrinsic pontine glioma following intensity-modulated radiation therapy: a case report.#251113
- Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer#910290
- Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma#1339035
- A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas#1364540
- A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT#807798
Record · ID 1351800
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive